LUMABS BV

Over LUMABS BV

LUMABS BV developed a new, solution-based platform using bioluminescent sensor proteins to detect biomolecules directly in blood plasma. The technology allows for automatic calibration and produces results with crude samples in a matter of minutes. The RAPPID version has been developed to replace multiple workflow, time consuming, waste generation steps in current ELISA methods with a simple one-step mix and measure method to rapidly and with the highest sensitivity of any detection technology, quantify the amount of the antibody/antigen of interest (e.g. drug) in a biological sample, such as blood, starting from a minimally invasive blood amount (1 μL).The test and reader provide a much higher accuracy as ELISA and eliminates the need for time consuming (washing) steps whilst also offering cost savings.

Using our patented technology, any immunoassay diagnostic manufacturer can reduce in >90% the current carbon footprint of the current ELISA methodologies through a quantifiable reduction in the use (waste) of plastics, (discharged liners of) liquid solutions and laboratory resources energy (no energy-consuming incubations, reduced worflow, reduced equipment usage, etc).

Trefwoorden

• Bioluminescense
• Bleia
• Bret
• Diagnostics
• Elisa
• Immunoassay
• Ivdr
• Lamp
• Ratiometric Analysis
• Therapeutical Drug Monitoring

Adres

• Hoofdkantoor

  Plesmanlaan 1251066CX AmsterdamNoord-Holland, Nederland

Team per functiegebied

Gebaseerd op 4 openbare functieprofielen, stand van 3 september 2026.

• Research / R&D2
• Engineering / Software Development1
• Executive / C-Suite1